Emerging Therapies for Nonalcoholic Fatty Liver Disease

被引:11
作者
Hameed, Bilal [1 ]
Terrault, Norah [1 ]
机构
[1] Univ Calif San Francisco, Div Gastroenterol, S357,513 Parnassus Ave, San Francisco, CA 94143 USA
关键词
Nonalcoholic fatty liver disease; FXR agonists; Insulin sensitizers; PPAR agonists; Antifibrotic agents; FARNESOID-X-RECEPTOR; TISSUE INSULIN-RESISTANCE; LYSYL OXIDASE; REMOGLIFLOZIN ETABONATE; OBETICHOLIC ACID; NUCLEAR RECEPTOR; ADIPOSE-TISSUE; HEPATIC STEATOSIS; HUMAN HEPATOCYTES; GLYCEMIC CONTROL;
D O I
10.1016/j.cld.2015.10.015
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Nonalcoholic fatty liver disease is the most common cause of liver disease in the United States. There are no drug therapies approved for the treatment of nonalcoholic steatohepatitis (NASH). Multiple different pathways are involved in the pathogenesis and each can be the target of the therapy. It is possible that more than 1 target is involved in disease development and progression. Multiple clinical trials with promising agents are underway. Because NASH is a slowly progressive disease and treatment likely to be of prolonged duration, acceptance and approval of any agent will require information on long-term clinical benefits and safety.
引用
收藏
页码:365 / +
页数:22
相关论文
共 98 条
  • [21] A chemical, genetic, and structural analysis of the nuclear bile acid receptor FXR
    Downes, M
    Verdecia, MA
    Roecker, AJ
    Hughes, R
    Hogenesch, JB
    Kast-Woelbern, HR
    Bowman, ME
    Ferrer, JL
    Anisfeld, AM
    Edwards, PA
    Rosenfeld, JM
    Alvarez, JGA
    Noel, JP
    Nicolaou, KC
    Evans, RM
    [J]. MOLECULAR CELL, 2003, 11 (04) : 1079 - 1092
  • [22] Incretin-Based Therapies for the Treatment of Type 2 Diabetes: Evaluation of the Risks and Benefits
    Drucker, Daniel J.
    Sherman, Steven I.
    Gorelick, Fred S.
    Bergenstal, Richard M.
    Sherwin, Robert S.
    Buse, John B.
    [J]. DIABETES CARE, 2010, 33 (02) : 428 - 433
  • [23] Alterations in adipose tissue and hepatic lipid kinetics in obese men and women with nonalcoholic fatty liver disease
    Fabbrini, Elisa
    Mohammed, B. Selma
    Magkos, Faidon
    Korenblat, Kevin M.
    Patterson, Bruce W.
    Klein, Samuel
    [J]. GASTROENTEROLOGY, 2008, 134 (02) : 424 - 431
  • [24] Intestinal FXR agonism promotes adipose tissue browning and reduces obesity and insulin resistance
    Fang, Sungsoon
    Suh, Jae Myoung
    Reilly, Shannon M.
    Yu, Elizabeth
    Osborn, Olivia
    Lackey, Denise
    Yoshihara, Eiji
    Perino, Alessia
    Jacinto, Sandra
    Lukasheva, Yelizaveta
    Atkins, Annette R.
    Khvat, Alexander
    Schnab, Bernd
    Yu, Ruth T.
    Brenner, David A.
    Coulter, Sally
    Liddle, Christopher
    Schoonjans, Kristina
    Olefsky, Jerrold M.
    Saltiel, Alan R.
    Downes, Michael
    Evans, Ronald M.
    [J]. NATURE MEDICINE, 2015, 21 (02) : 159 - 165
  • [25] IDENTIFICATION OF A NUCLEAR RECEPTOR THAT IS ACTIVATED BY FARNESOL METABOLITES
    FORMAN, BM
    GOODE, E
    CHEN, J
    ORO, AE
    BRADLEY, DJ
    PERLMANN, T
    NOONAN, DJ
    BURKA, LT
    MCMORRIS, T
    LAMPH, WW
    EVANS, RM
    WEINBERGER, C
    [J]. CELL, 1995, 81 (05) : 687 - 693
  • [26] Importance of Changes in Adipose Tissue Insulin Resistance to Histological Response During Thiazolidinedione Treatment of Patients with Nonalcoholic Steatohepatitis
    Gastaldelli, Amalia
    Harrison, Stephen A.
    Belfort-Aguilar, Renata
    Hardies, Lou Jean
    Balas, Bogdan
    Schenker, Steven
    Cusi, Kenneth
    [J]. HEPATOLOGY, 2009, 50 (04) : 1087 - 1093
  • [27] Angiotensin-receptor blockers as therapy for mild-to-moderate hypertension-associated non-alcoholic steatohepatitis
    Georgescu, Eugen Florin
    Ionescu, Reanina
    Niculescu, Mihaela
    Mogoanta, Laurentiu
    Vancica, Liliana
    [J]. WORLD JOURNAL OF GASTROENTEROLOGY, 2009, 15 (08) : 942 - 954
  • [28] Angiotensin receptor blockers in the treatment of NASH/NAFLD: Could they be a first-class option?
    Georgescu, Eugen Florin
    [J]. ADVANCES IN THERAPY, 2008, 25 (11) : 1141 - 1174
  • [29] Glucagon-Like Peptide-1 Receptor Is Present on Human Hepatocytes and Has a Direct Role in Decreasing Hepatic Steatosis In Vitro by Modulating Elements of the Insulin Signaling Pathway
    Gupta, Nitika Arora
    Mells, Jamie
    Dunham, Richard M.
    Grakoui, Arash
    Handy, Jeffrey
    Saxena, Neeraj Kumar
    Anania, Frank A.
    [J]. HEPATOLOGY, 2010, 51 (05) : 1584 - 1592
  • [30] Harrison SA, 2014, HEPATOLOGY, V60, p225A